Disease · MONDO_0040679
Comparisons in its trials87
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 87
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) vs Atezolizumab: deaths from any cause | 393 of 443 | 379 of 459 | 902 | NCT02302807 | Trial comparisons |
| Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) vs Atezolizumab: serious adverse events | 189 of 443 | 192 of 459 | 902 | NCT02302807 | Trial comparisons |
| OBSERVATION vs ATEZOLIZUMAB: deaths from any cause | 162 of 403 | 171 of 406 | 809 | NCT02450331 | Trial comparisons |
| OBSERVATION vs ATEZOLIZUMAB: serious adverse events | 72 of 398 | 122 of 390 | 788 | NCT02450331 | Trial comparisons |
| Ramucirumab + Docetaxel vs Placebo+Docetaxel: deaths from any cause | 193 of 258 | 209 of 265 | 523 | NCT02426125 | Trial comparisons |
| Ramucirumab + Docetaxel vs Placebo+Docetaxel: serious adverse events | 111 of 258 | 107 of 265 | 523 | NCT02426125 | Trial comparisons |
| Arm II (GCB) vs Arm I (GCP): deaths from any cause | 207 of 252 | 216 of 254 | 506 | NCT00942331 | Trial comparisons |
| Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo: Number of Participants Who Discontinue Study Treatment Due to an AE | 83 of 241 | 44 of 242 | 483 | NCT03898180 | Trial comparisons |
| Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo: Number of Participants Who Experience an AE | 234 of 241 | 235 of 242 | 483 | NCT03898180 | Trial comparisons |
| Arm II (GCB) vs Arm I (GCP): Number of Patients Experiencing Grade 3+ Toxicity | 183 of 237 | 163 of 232 | 469 | NCT00942331 | Trial comparisons |
| Arm II (GCB) vs Arm I (GCP): serious adverse events | 95 of 237 | 87 of 232 | 469 | NCT00942331 | Trial comparisons |
Part 2 Dose Expansion: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w vs Part 4 Dose Expansion of NKTR-214 + Nivolumab + Ipilimumab: Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D) | 64 of 429 | 3 of 17 | 446 | NCT02983045 | Trial comparisons |
| Ramucirumab + Docetaxel vs Placebo + Docetaxel: Number of Participants With Anti-Ramucirumab Antibodies | 3 of 199 | 8 of 213 | 412 | NCT02426125 | Trial comparisons |
| Experimental Arm: Arm A vs Control Arm: Arm B: deaths from any cause | 78 of 99 | 86 of 101 | 200 | NCT01780545 | Trial comparisons |
| Experimental Arm: Arm A vs Control Arm: Arm B: serious adverse events | 56 of 99 | 45 of 101 | 200 | NCT01780545 | Trial comparisons |
| Rogaratinib (BAY1163877) vs Chemotherapy: deaths from any cause | 47 of 86 | 45 of 82 | 168 | NCT03410693 | Trial comparisons |
| Rogaratinib (BAY1163877) vs Chemotherapy: serious adverse events | 39 of 86 | 33 of 82 | 168 | NCT03410693 | Trial comparisons |
| Durva + Olaparib vs Durva + Placebo: deaths from any cause | 52 of 78 | 46 of 76 | 154 | NCT03459846 | Trial comparisons |
| Durva + Olaparib vs Durva + Placebo: serious adverse events | 37 of 76 | 26 of 76 | 152 | NCT03459846 | Trial comparisons |
| DN24-02 vs Standard of Care: deaths from any cause | 30 of 67 | 30 of 72 | 139 | NCT01353222 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0040679/comparisons